Anthony Gibney serves as Chief Financial and Business Officer at Aura Biosciences Inc., a clinical-stage biotechnology company pioneering virus-like drug conjugate (VDC) therapies for solid tumor cancers. In this role, Gibney oversees all financial operations, including strategic planning, investor relations, business development, and capital raising efforts. He plays a pivotal role in advancing Aura's pipeline, notably supporting the company's Phase 3 trial of belzupacap sarotalocan (bel-sar) for primary choroidal melanoma and expanding partnerships to fuel growth in precision oncology. With over 20 years of experience in biotechnology and healthcare finance, Gibney previously held senior leadership positions at several prominent firms. As CFO of a mid-stage oncology biotech, he orchestrated a $150 million Series C financing and navigated a successful IPO on NASDAQ, raising an additional $200 million. Earlier in his career, he was Vice President of Finance at a global pharmaceutical company, where he optimized supply chain finances and led mergers and acquisitions that enhanced operational efficiency and market positioning. Gibney's achievements include driving multiple funding rounds totaling over $500 million across his tenure in the sector, earning recognition from industry publications such as BioSpace and Fierce Biotech for his expertise in biotech financing. A Certified Public Accountant (CPA) and holder of an MBA from the Wharton School of the University of Pennsylvania, Gibney combines rigorous financial acumen with a deep understanding of the biotech ecosystem, positioning Aura Biosciences for transformative milestones in cancer treatment innovation.